Publication

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands

Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Coenen, J. L. L. M., van den Berg, H. P. P., Mehra, N., van Oort, I. M., Fossion, L. M. C. L., Hendriks, M. P., Bloemendal, H. J., van de Luijtgaarden, A. C. M., Huinink, D. T. B., van den Bergh, A. C. M. F., van den Bosch, J., Polee, M. B., Weijl, N., Bergman, A. M., Uyl-de Groot, C. A. & Gerritsen, W. R., Oct-2019, In : Clinical genitourinary cancer. 17, 5, p. E946-E956 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Coenen, J. L. L. M., van den Berg, H. P. P., Mehra, N., van Oort, I. M., Fossion, L. M. C. L., Hendriks, M. P., Bloemendal, H. J., van de Luijtgaarden, A. C. M., Huinink, D. T. B., van den Bergh, A. C. M. F., van den Bosch, J., Polee, M. B., Weijl, N., Bergman, A. M., Uyl-de Groot, C. A., & Gerritsen, W. R. (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical genitourinary cancer, 17(5), E946-E956. https://doi.org/10.1016/j.clgc.2019.05.018

Author

Westgeest, Hans M. ; Kuppen, Malou C. P. ; van den Eertwegh, Alphonsus J. M. ; de Wit, Ronald ; Coenen, Juleon L. L. M. ; van den Berg, H. P. (Pieter) ; Mehra, Niven ; van Oort, Inge M. ; Fossion, Laurent M. C. L. ; Hendriks, Mathijs P. ; Bloemendal, Haiko J. ; van de Luijtgaarden, Addy C. M. ; Huinink, Daan ten Bokkel ; van den Bergh, A. C. M. (Fons) ; van den Bosch, Joan ; Polee, Marco B. ; Weijl, Nir ; Bergman, Andre M. ; Uyl-de Groot, Carin A. ; Gerritsen, Winald R. / Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI : Observational Study in the Netherlands. In: Clinical genitourinary cancer. 2019 ; Vol. 17, No. 5. pp. E946-E956.

Harvard

Westgeest, HM, Kuppen, MCP, van den Eertwegh, AJM, de Wit, R, Coenen, JLLM, van den Berg, HPP, Mehra, N, van Oort, IM, Fossion, LMCL, Hendriks, MP, Bloemendal, HJ, van de Luijtgaarden, ACM, Huinink, DTB, van den Bergh, ACMF, van den Bosch, J, Polee, MB, Weijl, N, Bergman, AM, Uyl-de Groot, CA & Gerritsen, WR 2019, 'Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands', Clinical genitourinary cancer, vol. 17, no. 5, pp. E946-E956. https://doi.org/10.1016/j.clgc.2019.05.018

Standard

Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI : Observational Study in the Netherlands. / Westgeest, Hans M.; Kuppen, Malou C. P.; van den Eertwegh, Alphonsus J. M.; de Wit, Ronald; Coenen, Juleon L. L. M.; van den Berg, H. P. (Pieter); Mehra, Niven; van Oort, Inge M.; Fossion, Laurent M. C. L.; Hendriks, Mathijs P.; Bloemendal, Haiko J.; van de Luijtgaarden, Addy C. M.; Huinink, Daan ten Bokkel; van den Bergh, A. C. M. (Fons); van den Bosch, Joan; Polee, Marco B.; Weijl, Nir; Bergman, Andre M.; Uyl-de Groot, Carin A.; Gerritsen, Winald R.

In: Clinical genitourinary cancer, Vol. 17, No. 5, 10.2019, p. E946-E956.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Westgeest HM, Kuppen MCP, van den Eertwegh AJM, de Wit R, Coenen JLLM, van den Berg HPP et al. Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical genitourinary cancer. 2019 Oct;17(5):E946-E956. https://doi.org/10.1016/j.clgc.2019.05.018


BibTeX

@article{f99c5aaf9c744512838bf4ed61f11443,
title = "Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands",
abstract = "In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.Background: Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. However, trial populations may not reflect the real-world population. We compared patient characteristics and outcomes of cabazitaxel within and outside trials (standard of care, SOC). Patients and Methods: mCRPC patients treated with cabazitaxel directly after docetaxel therapy before 2017 were retrospectively identified and followed to 2018. Patients were grouped on the basis of treatment within a trial or SOC. Outcomes included OS and prostate-specific antigen (PSA) response. Results: From 3616 patients in the CAPRI registry, we identified 356 patients treated with cabazitaxel, with 173 patients treated in the second line. Trial patients had favorable prognostic factors: fewer symptoms, less visceral disease, lower lactate dehydrogenase, higher hemoglobin, more docetaxel cycles, and longer treatment-free interval since docetaxel therapy. PSA response (>= 50% decline) was 28 versus 12%, respectively (P = .209). Median OS was 13.6 versus 9.6 months for trial and SOC subgroups, respectively (hazard ratio = 0.73, P =.067). After correction for prognostic factors, there was no difference in survival (hazard ratio = 1.00, P = .999). Longer duration of androgen deprivation therapy treatment, lower lactate dehydrogenase, and lower PSA were associated with longer OS; visceral disease had a trend for shorter OS. Conclusion: Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This underlines the importance of adequate estimation of trial eligibility and health status of mCRPC patients in daily practice to ensure optimal outcomes. (C) 2019 Elsevier Inc. All rights reserved.",
keywords = "Postdocetaxel, Real-world outcomes, Registry, Trial eligibility, Trial population, OPEN-LABEL, ABIRATERONE ACETATE, INCREASED SURVIVAL, PLUS PREDNISONE, DOCETAXEL, MEN, CHEMOTHERAPY, CYCLES, SAFETY, POSTDOCETAXEL",
author = "Westgeest, {Hans M.} and Kuppen, {Malou C. P.} and {van den Eertwegh}, {Alphonsus J. M.} and {de Wit}, Ronald and Coenen, {Juleon L. L. M.} and {van den Berg}, {H. P. (Pieter)} and Niven Mehra and {van Oort}, {Inge M.} and Fossion, {Laurent M. C. L.} and Hendriks, {Mathijs P.} and Bloemendal, {Haiko J.} and {van de Luijtgaarden}, {Addy C. M.} and Huinink, {Daan ten Bokkel} and {van den Bergh}, {A. C. M. (Fons)} and {van den Bosch}, Joan and Polee, {Marco B.} and Nir Weijl and Bergman, {Andre M.} and {Uyl-de Groot}, {Carin A.} and Gerritsen, {Winald R.}",
year = "2019",
month = oct,
doi = "10.1016/j.clgc.2019.05.018",
language = "English",
volume = "17",
pages = "E946--E956",
journal = "Clinical genitourinary cancer",
issn = "1558-7673",
publisher = "CIG MEDIA GROUP, LP",
number = "5",

}

RIS

TY - JOUR

T1 - Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI

T2 - Observational Study in the Netherlands

AU - Westgeest, Hans M.

AU - Kuppen, Malou C. P.

AU - van den Eertwegh, Alphonsus J. M.

AU - de Wit, Ronald

AU - Coenen, Juleon L. L. M.

AU - van den Berg, H. P. (Pieter)

AU - Mehra, Niven

AU - van Oort, Inge M.

AU - Fossion, Laurent M. C. L.

AU - Hendriks, Mathijs P.

AU - Bloemendal, Haiko J.

AU - van de Luijtgaarden, Addy C. M.

AU - Huinink, Daan ten Bokkel

AU - van den Bergh, A. C. M. (Fons)

AU - van den Bosch, Joan

AU - Polee, Marco B.

AU - Weijl, Nir

AU - Bergman, Andre M.

AU - Uyl-de Groot, Carin A.

AU - Gerritsen, Winald R.

PY - 2019/10

Y1 - 2019/10

N2 - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.Background: Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. However, trial populations may not reflect the real-world population. We compared patient characteristics and outcomes of cabazitaxel within and outside trials (standard of care, SOC). Patients and Methods: mCRPC patients treated with cabazitaxel directly after docetaxel therapy before 2017 were retrospectively identified and followed to 2018. Patients were grouped on the basis of treatment within a trial or SOC. Outcomes included OS and prostate-specific antigen (PSA) response. Results: From 3616 patients in the CAPRI registry, we identified 356 patients treated with cabazitaxel, with 173 patients treated in the second line. Trial patients had favorable prognostic factors: fewer symptoms, less visceral disease, lower lactate dehydrogenase, higher hemoglobin, more docetaxel cycles, and longer treatment-free interval since docetaxel therapy. PSA response (>= 50% decline) was 28 versus 12%, respectively (P = .209). Median OS was 13.6 versus 9.6 months for trial and SOC subgroups, respectively (hazard ratio = 0.73, P =.067). After correction for prognostic factors, there was no difference in survival (hazard ratio = 1.00, P = .999). Longer duration of androgen deprivation therapy treatment, lower lactate dehydrogenase, and lower PSA were associated with longer OS; visceral disease had a trend for shorter OS. Conclusion: Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This underlines the importance of adequate estimation of trial eligibility and health status of mCRPC patients in daily practice to ensure optimal outcomes. (C) 2019 Elsevier Inc. All rights reserved.

AB - In the Dutch CAPRI registry, cabazitaxel treatment as the standard of care and in trials was analyzed. Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This may be explained by a worse prognosis at cabazitaxel initiation.Background: Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. However, trial populations may not reflect the real-world population. We compared patient characteristics and outcomes of cabazitaxel within and outside trials (standard of care, SOC). Patients and Methods: mCRPC patients treated with cabazitaxel directly after docetaxel therapy before 2017 were retrospectively identified and followed to 2018. Patients were grouped on the basis of treatment within a trial or SOC. Outcomes included OS and prostate-specific antigen (PSA) response. Results: From 3616 patients in the CAPRI registry, we identified 356 patients treated with cabazitaxel, with 173 patients treated in the second line. Trial patients had favorable prognostic factors: fewer symptoms, less visceral disease, lower lactate dehydrogenase, higher hemoglobin, more docetaxel cycles, and longer treatment-free interval since docetaxel therapy. PSA response (>= 50% decline) was 28 versus 12%, respectively (P = .209). Median OS was 13.6 versus 9.6 months for trial and SOC subgroups, respectively (hazard ratio = 0.73, P =.067). After correction for prognostic factors, there was no difference in survival (hazard ratio = 1.00, P = .999). Longer duration of androgen deprivation therapy treatment, lower lactate dehydrogenase, and lower PSA were associated with longer OS; visceral disease had a trend for shorter OS. Conclusion: Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This underlines the importance of adequate estimation of trial eligibility and health status of mCRPC patients in daily practice to ensure optimal outcomes. (C) 2019 Elsevier Inc. All rights reserved.

KW - Postdocetaxel

KW - Real-world outcomes

KW - Registry

KW - Trial eligibility

KW - Trial population

KW - OPEN-LABEL

KW - ABIRATERONE ACETATE

KW - INCREASED SURVIVAL

KW - PLUS PREDNISONE

KW - DOCETAXEL

KW - MEN

KW - CHEMOTHERAPY

KW - CYCLES

KW - SAFETY

KW - POSTDOCETAXEL

U2 - 10.1016/j.clgc.2019.05.018

DO - 10.1016/j.clgc.2019.05.018

M3 - Article

VL - 17

SP - E946-E956

JO - Clinical genitourinary cancer

JF - Clinical genitourinary cancer

SN - 1558-7673

IS - 5

ER -

ID: 99961432